Related Experiment Videos
Abstract:
Viruses capable of inducing lysis of malignant cells through their replication process are known as "oncolytic" viruses. Clinical trials in oncology have been performed with oncolytic viruses for nearly fifty years. Both systemic and intratumoral routes of administration have been explored. Toxicity has generally been limited to injection site pain, transient fever and tumor necrosis. Responses with early crude materials were usually short in duration; however, recent trials with gene attenuated viruses suggest more prolonged duration to responses observed.
Insights
Oncolytic viruses, which destroy cancer cells, have been studied for 50 years in clinical oncology trials. Newer gene-attenuated oncolytic virus therapies show promise for longer-lasting anti-cancer responses with manageable side effects.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Oncolytic viruses are engineered or naturally occurring viruses that selectively infect and lyse cancer cells.
- Clinical research into oncolytic virotherapy for cancer has a history spanning approximately fifty years.
- Both systemic and direct intratumoral administration methods have been investigated for oncolytic virus delivery.
Purpose of the Study:
- To review the historical and current landscape of oncolytic virus therapy in oncology.
- To summarize the observed toxicities and response durations associated with oncolytic virus treatments.
- To highlight the potential of advanced oncolytic virus strategies, such as gene attenuation, in improving therapeutic outcomes.
Main Methods:
- Review of clinical trial data and scientific literature on oncolytic viruses in cancer treatment.
- Analysis of administration routes (systemic vs. intratumoral) and their implications.
- Evaluation of toxicity profiles and duration of response in patients treated with oncolytic viruses.
Main Results:
- Toxicity associated with oncolytic viruses is generally mild, including injection site pain, fever, and tumor necrosis.
- Early studies using less refined oncolytic virus preparations reported transient responses.
- Recent clinical trials employing gene-attenuated oncolytic viruses indicate the potential for more durable and prolonged therapeutic responses.
Conclusions:
- Oncolytic virus therapy represents a long-standing and evolving approach in cancer treatment.
- Gene attenuation strategies in oncolytic viruses may enhance the duration and efficacy of anti-cancer responses.
- Further research and clinical trials are warranted to optimize oncolytic virus therapies for improved patient outcomes.